Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
Recruiting · NCT05859191 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Tours
View the official record on ClinicalTrials.gov →Interventions studied
Blood sample
What this trial is about
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Age ≥ 18 years
- Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
- Lupus patient, newly diagnosed or known, untreated or in relapse
- Lupus patient considered stable by the treating practitioner
- Requiring blood sampling for follow-up
Exclusion criteria
- Main autoimmune disease other than lupus
- Patient under legal protection, guardianship or curators
- Opposition to data processing
Where it is running
1 location listed.
- University Hospital - Tours, France